Tags

Type your tag names separated by a space and hit enter

PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome.
Histopathology. 2018 Oct; 73(4):573-584.H

Abstract

AIMS

Expression profiles and clinical impact of programmed cell death ligand 1 (PD-L1) and programmed cell death 1 (PD-1) expressing tumour infiltrating lymphocytes (TILs) in head and neck squamous cell carcinoma (HNSCC) are not elucidated fully. This study evaluates expression patterns in primary HNSCC and related lymph node metastasis and the impact on patients' clinical outcome.

METHODS AND RESULTS

Immunohistochemical staining patterns of PD-L1 and PD-1 were evaluated in 129 specimens of primary HNSCC and 77 lymph node metastases. Results were correlated with patients' clinical data. PD-L1 expression was observed in 36% of primary carcinoma and 33% of lymph node metastasis, and correlates significantly with decreased overall survival (OS) (P = 0.01) and disease-free survival (DFS) (P = 0.001) in oral cavity squamous cell carcinoma patients. PD-L1 expression was associated with presence of lymph node metastasis (P = 0.0223). Infiltration of PD-1-expressing lymphocytes correlates significantly with favourable OS (P = 0.001) and DFS (P = 0.001) in oropharyngeal cancer and hypopharyngeal cancer patients OS (P = 0.007) and DFS (P = 0.001). Presence of PD-1 TILs also correlates significantly with better OS (P = 0.005) and DFS (P = 0) in the human papilloma virus (HPV)-negative cohort. Cox regression multivariate analysis revealed PD-1 TIL expression as an independent prognostic marker for OS (P = 0.004) and DFS (P = 0.001) and T stage was validated as negative prognostic marker for OS (P = 0.011). PD-1-expressing lymphocytes (P = 0.0412) and PD-L1 expression (P = 0.0022) patterns correlate significantly in primary cancers and matched lymph node metastases.

CONCLUSIONS

Our results characterise the expression profiles of PD-1 axis proteins in HNSCC which might serve as possible clinical prognostic markers.

Authors+Show Affiliations

Department of Otorhinolaryngology, Head and Neck Surgery, Vienna, Austria.Department of Otorhinolaryngology, Head and Neck Surgery, Vienna, Austria.Department of Experimental Pathology and Laboratory Animal Pathology, Medical University of Vienna, Vienna, Austria.Department of Experimental Pathology and Laboratory Animal Pathology, Medical University of Vienna, Vienna, Austria. Department of Laboratory Animal Pathology, University of Veterinary Medicine of Vienna, Vienna, Austria. Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria.Department of Radiotherapy, Vienna, Austria.Department of Medicine I, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria.Department of Medicine I, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria.Department of Medicine I, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria.Department of Medicine I, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria.Department of Otorhinolaryngology, Head and Neck Surgery, Vienna, Austria.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

29742291

Citation

Schneider, Sven, et al. "PD-1 and PD-L1 Expression in HNSCC Primary Cancer and Related Lymph Node Metastasis - Impact On Clinical Outcome." Histopathology, vol. 73, no. 4, 2018, pp. 573-584.
Schneider S, Kadletz L, Wiebringhaus R, et al. PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome. Histopathology. 2018;73(4):573-584.
Schneider, S., Kadletz, L., Wiebringhaus, R., Kenner, L., Selzer, E., Füreder, T., Rajky, O., Berghoff, A. S., Preusser, M., & Heiduschka, G. (2018). PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome. Histopathology, 73(4), 573-584. https://doi.org/10.1111/his.13646
Schneider S, et al. PD-1 and PD-L1 Expression in HNSCC Primary Cancer and Related Lymph Node Metastasis - Impact On Clinical Outcome. Histopathology. 2018;73(4):573-584. PubMed PMID: 29742291.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome. AU - Schneider,Sven, AU - Kadletz,Lorenz, AU - Wiebringhaus,Robert, AU - Kenner,Lukas, AU - Selzer,Edgar, AU - Füreder,Thorsten, AU - Rajky,Orsolya, AU - Berghoff,Anna S, AU - Preusser,Matthias, AU - Heiduschka,Gregor, Y1 - 2018/07/04/ PY - 2017/12/16/received PY - 2018/04/24/revised PY - 2018/05/04/accepted PY - 2018/5/10/pubmed PY - 2019/1/19/medline PY - 2018/5/10/entrez KW - HNSCC KW - PD-1 KW - PD-L1 KW - TIL KW - immunohistochemistry KW - lymph node metastasis SP - 573 EP - 584 JF - Histopathology JO - Histopathology VL - 73 IS - 4 N2 - AIMS: Expression profiles and clinical impact of programmed cell death ligand 1 (PD-L1) and programmed cell death 1 (PD-1) expressing tumour infiltrating lymphocytes (TILs) in head and neck squamous cell carcinoma (HNSCC) are not elucidated fully. This study evaluates expression patterns in primary HNSCC and related lymph node metastasis and the impact on patients' clinical outcome. METHODS AND RESULTS: Immunohistochemical staining patterns of PD-L1 and PD-1 were evaluated in 129 specimens of primary HNSCC and 77 lymph node metastases. Results were correlated with patients' clinical data. PD-L1 expression was observed in 36% of primary carcinoma and 33% of lymph node metastasis, and correlates significantly with decreased overall survival (OS) (P = 0.01) and disease-free survival (DFS) (P = 0.001) in oral cavity squamous cell carcinoma patients. PD-L1 expression was associated with presence of lymph node metastasis (P = 0.0223). Infiltration of PD-1-expressing lymphocytes correlates significantly with favourable OS (P = 0.001) and DFS (P = 0.001) in oropharyngeal cancer and hypopharyngeal cancer patients OS (P = 0.007) and DFS (P = 0.001). Presence of PD-1 TILs also correlates significantly with better OS (P = 0.005) and DFS (P = 0) in the human papilloma virus (HPV)-negative cohort. Cox regression multivariate analysis revealed PD-1 TIL expression as an independent prognostic marker for OS (P = 0.004) and DFS (P = 0.001) and T stage was validated as negative prognostic marker for OS (P = 0.011). PD-1-expressing lymphocytes (P = 0.0412) and PD-L1 expression (P = 0.0022) patterns correlate significantly in primary cancers and matched lymph node metastases. CONCLUSIONS: Our results characterise the expression profiles of PD-1 axis proteins in HNSCC which might serve as possible clinical prognostic markers. SN - 1365-2559 UR - https://www.unboundmedicine.com/medline/citation/29742291/PD_1_and_PD_L1_expression_in_HNSCC_primary_cancer_and_related_lymph_node_metastasis___impact_on_clinical_outcome_ L2 - https://doi.org/10.1111/his.13646 DB - PRIME DP - Unbound Medicine ER -